China’s first self-developed mRNA vaccine to enter mass production in October with annual capacity of 200 million doses
China’s first production base for an mRNA vaccine against COVID-19,
which uses domestically produced core raw materials and equipment,
is expected to be put into use in October.
Experts said that this proves
China has grasped core mRNA vaccine technology, and it will boost the country’s mass vaccination drive.
Jointly developed by the Academy of Military Medical Sciences,
Suzhou Abogen and
Yunnan Walvax Biotechnology Co,the mRNA vaccine called ARCoVax
is expected to go into mass production in the base in Yuxi, Southwest China’s Yunnan Province next month.
With an investment of 520 million yuan ($80 million), the plant, China’s first production base for mRNA vaccine,
has the capacity to produce 200 million doses annually.
Compared with mRNA vaccines developed by the US and Germany,
the domestic mRNA vaccine is much safer as the selection of the vaccine antigen target is more precise and the neutralizing antibodies induced are higher,
media reports said.
The storage cost of this vaccine
is lower than those from overseas as it adopts a single injection in one package
and could be stored at room temperature for a week or at 4 C for a long time, making it easier to use.
A Beijing-based immunologist told the Global Times on Thursday that
the domestically produced mRNA vaccine demonstrates China’s huge improvements in mRNA technology and the country’s leading position in biotechnology.
ARCoVax has been approved to initiate its late-stage clinical trials in Mexico and Indonesia
by local health authorities, Yunnan Walvax Biotechnology Co announced on August 31.
Global Times
https://www.globaltimes.cn/page/202109/1233797.shtml
Mexico to start late-stage clinical trial for China’s mRNA COVID-19 vaccine
MEXICO CITY (Reuters)
Mexico plans to start a late-stage clinical trial this month for a COVID-19 vaccine candidate developed by China using similar technology to shots from Moderna and Pfizer,foreign minister Marcelo Ebrard said on Tuesday.
The phase III trial for the shot from China’s Walvax Biotechnology using messenger RNA (mRNA) technology will start on May 30 and involve 6,000 volunteers, Ebrard said in a Tweet.
https://ca.movies.yahoo.com/mexico-start-phase-iii-clinical-123058946.html